A Comparison of the Efficacy of Antivenoms and Varespladib against the In Vitro Pre-Synaptic Neurotoxicity of Thai and Javanese Russell's Viper (Daboia spp.) Venoms.

Autor: Lay, Mimi¹ (AUTHOR) mimi.lay@monash.edu, Hodgson, Wayne C.¹ (AUTHOR) wayne.hodgson@monash.edu

Publikováno v: Toxins. Mar2024, Vol. 16 Issue 3, p124. 18p.

Isolation and Pharmacological Characterisation of Pre-Synaptic Neurotoxins from Thai and Javanese Russell's Viper (Daboia siamensis) Venoms.

Autor: Lay, Mimi¹ (AUTHOR) mimi.lay@monash.edu, Hodgson, Wayne C.¹ (AUTHOR) wayne.hodgson@monash.edu

Publikováno v: Toxins. Sep2024, Vol. 16 Issue 9, p405. 20p.

Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.

Autor: Geng LN; Department of Medicine, Stanford University School of Medicine, Stanford, California., Bonilla H; Department of Medicine, Stanford University School of Medicine, Stanford, California., Hedlin H; Department of Medicine, Stanford University School of Medicine, Stanford, California., Jacobson KB; Department of Medicine, Stanford University School of Medicine, Stanford, California.; Kaiser Permanente Northern California Division of Research, Oakland., Tian L; Department of Biomedical Data Science, Stanford School of Medicine, Stanford, California., Jagannathan P; Department of Medicine, Stanford University School of Medicine, Stanford, California., Yang PC; Department of Medicine, Stanford University School of Medicine, Stanford, California., Subramanian AK; Department of Medicine, Stanford University School of Medicine, Stanford, California., Liang JW; Department of Medicine, Stanford University School of Medicine, Stanford, California., Shen S; Department of Medicine, Stanford University School of Medicine, Stanford, California., Deng Y; Department of Medicine, Stanford University School of Medicine, Stanford, California., Shaw BJ; Department of Medicine, Stanford University School of Medicine, Stanford, California., Botzheim B; Department of Medicine, Stanford University School of Medicine, Stanford, California., Desai M; Department of Medicine, Stanford University School of Medicine, Stanford, California., Pathak D; Department of Medicine, Stanford University School of Medicine, Stanford, California., Jazayeri Y; Department of Medicine, Stanford University School of Medicine, Stanford, California., Thai D; Department of Medicine, Stanford University School of Medicine, Stanford, California., O'Donnell A; Department of Medicine, Stanford University School of Medicine, Stanford, California., Mohaptra S; Department of Medicine, Stanford University School of Medicine, Stanford, California., Leang Z; Department of Medicine, Stanford University School of Medicine, Stanford, California., Reynolds GZM; Department of Medicine, Stanford University School of Medicine, Stanford, California., Brooks EF; Department of Medicine, Stanford University School of Medicine, Stanford, California., Bhatt AS; Department of Medicine, Stanford University School of Medicine, Stanford, California., Shafer RW; Department of Medicine, Stanford University School of Medicine, Stanford, California., Miglis MG; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California., Quach T; Stanford University, Stanford, California., Tiwari A; Stanford University, Stanford, California., Banerjee A; Pfizer Research and Development, Pfizer Inc, Cambridge, Massachusetts., Lopez RN; Clinical Research Collaborations COE, Worldwide Medical and Safety, Pfizer Inc, Groton, Connecticut., De Jesus M; Strategic Planning, Worldwide Medical and Safety, Pfizer Inc, New York, New York., Charnas LR; Clinical Research Collaborations COE, Worldwide Medical and Safety, Pfizer Inc, Groton, Connecticut., Utz PJ; Department of Medicine, Stanford University School of Medicine, Stanford, California.; Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, California., Singh U; Department of Medicine, Stanford University School of Medicine, Stanford, California.; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California.

Publikováno v: JAMA internal medicine [JAMA Intern Med] 2024 Sep 01; Vol. 184 (9), pp. 1024-1034.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors.

Autor: Odegard JM; Biomarker Sciences, Gilead Sciences Inc, Seattle, Washington, USA jared.odegard@gmail.com., Othman AA; Clinical Pharmacology, Gilead Sciences Inc, Foster City, California, USA., Lin KW; Gilead Sciences, Inc, Foster City, California, USA., Wang AY; Gilead Sciences, Inc, Foster City, California, USA., Nazareno J; Gilead Sciences, Inc, Foster City, California, USA., Yoon OK; Gilead Sciences, Inc, Foster City, California, USA., Ling J; Gilead Sciences, Inc, Foster City, California, USA., Lad L; Gilead Sciences, Inc, Foster City, California, USA., Dunbar PR; School of Biological Sciences and Maurice Wilkins Centre, The University of Auckland, Auckland, New Zealand., Thai D; Gilead Sciences, Inc, Foster City, California, USA., Ang E; University of Auckland, Auckland, New Zealand., Waldron N; University of Auckland, Auckland, New Zealand., Deva S; University of Auckland, Auckland, New Zealand.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Apr 11; Vol. 12 (4). Date of Electronic Publication: 2024 Apr 11.